Evogene (EVGN) Expected to Post Quarterly Earnings on Tuesday

Evogene (NASDAQ:EVGN) is expected to post its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect the company to post earnings of ($0.27) per share and revenue of $0.3250 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 9:00 AM ET.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Saturday, May 16th. The biotechnology company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.33). Evogene had a negative net margin of 638.12% and a negative return on equity of 158.82%. The firm had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.35 million.

Evogene Trading Up 5.4%

EVGN stock opened at $0.63 on Tuesday. The firm’s 50-day moving average price is $0.53 and its two-hundred day moving average price is $0.73. The stock has a market capitalization of $5.51 million, a price-to-earnings ratio of -0.45 and a beta of 1.40. Evogene has a 12-month low of $0.37 and a 12-month high of $1.50.

Institutional Investors Weigh In On Evogene

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in shares of Evogene during the 4th quarter valued at $25,000. Jane Street Group LLC grew its stake in shares of Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 12,387 shares during the last quarter. Finally, Citadel Advisors LLC grew its holdings in shares of Evogene by 169.4% in the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 36,206 shares during the last quarter. Institutional investors own 10.40% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evogene in a report on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.